Chiara Battistini
Research Subjects
Chiara Battistini has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Ugo Cavallaro
Unit of Gynecological Oncology Research, European Institute of Oncology IRCCS, Milan, Italy
27 shared publications - Ernst Lengyel
Department of Obstetrics and Gynecology/Section of Gynecologic Oncology, The University of Chicago, Chicago, IL, USA
23 shared publications - Beatrice Malacrida
Barts Cancer Institute, Queen Mary University of London, Charterhouse Square London ECM1 6BQ, UK
22 shared publications - Carman Ka Man Ip
Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
22 shared publications - Frances R. Balkwill
Queen Mary University of London
22 shared publications - Hilary A. Kenny
Department of Obstetrics and Gynecology/Section of Gynecologic Oncology, The University of Chicago, Chicago, IL, USA
22 shared publications
Latest Publications
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 10 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth
Inactive combinatorial screens
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 10 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth
Inactive combinatorial screens
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 8 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth
Drug response curves of the confirmatory screen dose-response screen
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 8 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth
Drug response curves of the confirmatory screen dose-response screen
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Data from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth
High-grade serous ovarian cancer is generally treated with upfront chemotherapy, including carboplatin. The persistence of platinum-resistant cells drives recurrent disease. A high-throughput screen using a 3D organotypic culture assembled with extracellular matrix, primary human fibroblasts, and mesothelial cells was established and validated. Using a library of FDA-approved drugs, the 3D high-throughput screen was performed with the goal of identifying a combination of drugs that synergistically target two populations of ovarian cancer: aldehyde dehydrogenase (ALDH) high (ALDHhi) and ALDH low (ALDHlo) enzyme activity cells, which are less sensitive to carboplatin treatment than the bulk ovarian cancer cells. Initial results showed that omipalisib, verteporfin, CA3, mitoxantrone, navitoclax, venetoclax, and YM155 had significant single-drug activity in either the ALDHlo or both the ALDHlo/ALDHhi cell populations. Synergistic drug activity was identified with three drug combinations: navitoclax/omipalisib, navitoclax/YM155, and YM155/omipalisib. In vitro, the combination of navitoclax/YM155 was most efficient at blocking primary human ovarian cancer sphere formation and the proliferation of four different ovarian cancer cell lines in the 3D organotypic culture. In vivo, the combination of navitoclax/YM155/carboplatin decreased ovarian cancer metastasis, decreased the percentage of ALDHhi ovarian cancer cells in tumors, and increased survival when compared with carboplatin treatment alone in xenograft models. Our results suggest that the combination of navitoclax/YM155/carboplatin has promise as a therapy for treating ovarian cancer.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth
High-grade serous ovarian cancer is generally treated with upfront chemotherapy, including carboplatin. The persistence of platinum-resistant cells drives recurrent disease. A high-throughput screen using a 3D organotypic culture assembled with extracellular matrix, primary human fibroblasts, and mesothelial cells was established and validated. Using a library of FDA-approved drugs, the 3D high-throughput screen was performed with the goal of identifying a combination of drugs that synergistically target two populations of ovarian cancer: aldehyde dehydrogenase (ALDH) high (ALDHhi) and ALDH low (ALDHlo) enzyme activity cells, which are less sensitive to carboplatin treatment than the bulk ovarian cancer cells. Initial results showed that omipalisib, verteporfin, CA3, mitoxantrone, navitoclax, venetoclax, and YM155 had significant single-drug activity in either the ALDHlo or both the ALDHlo/ALDHhi cell populations. Synergistic drug activity was identified with three drug combinations: navitoclax/omipalisib, navitoclax/YM155, and YM155/omipalisib. In vitro, the combination of navitoclax/YM155 was most efficient at blocking primary human ovarian cancer sphere formation and the proliferation of four different ovarian cancer cell lines in the 3D organotypic culture. In vivo, the combination of navitoclax/YM155/carboplatin decreased ovarian cancer metastasis, decreased the percentage of ALDHhi ovarian cancer cells in tumors, and increased survival when compared with carboplatin treatment alone in xenograft models. Our results suggest that the combination of navitoclax/YM155/carboplatin has promise as a therapy for treating ovarian cancer.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth
16 h combinatorial drug screen
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth
16 h combinatorial drug screen
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth
Sphere-forming capability of ALDH populations
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth
Sphere-forming capability of ALDH populations
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 12 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth
Combinatorial testing in 3D tetraculture
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 12 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth
Combinatorial testing in 3D tetraculture
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth
72 h combinatorial drug screen
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth
72 h combinatorial drug screen
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 9 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth
Combinatorial screens of active compounds
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 9 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth
Combinatorial screens of active compounds
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth
Carboplatin response of ALDH populations
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth
Carboplatin response of ALDH populations
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 13 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth
Immunoblot analysis of drug targets
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 13 from Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth
Immunoblot analysis of drug targets